vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2018-4-54-60vtio-950Research ArticleКлинические наблюденияClinical CasesОпыт эффективной противовирусной терапии у реципиента печени с возвратной HCV-инфекцией 1-го генотипаExperience of effective antiviral therapy in a liver recipient with recurrent HCV infection genotype 1УмрикД. В.UmrikD. V.

123182, Москва, ул. Щукинская, д. 1. Тел. (926) 434-16-24. 

1, Shchukinskaya str., Moscow, 123182. Tel. (926) 434-16-24.

d_ipatova@mail.ruЦирульниковаО. М.TsiroulnikovaO. M.

Москва

Moscow

МилосердовИ. А.MiloserdovI. A.

Москва

Moscow

ЛатыповР. А.LatypovR. A.

Москва

Moscow

ЕгороваЕ. Т.EgorovaE. T.

Москва

Moscow

ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationRussian FederationФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)Russian Federation2018300120192045460Copyright © Умрик Д.В., Цирульникова О.М., Милосердов И.А., Латыпов Р.А., Егорова Е.Т., 20192019Умрик Д.В., Цирульникова О.М., Милосердов И.А., Латыпов Р.А., Егорова Е.Т.Umrik D.V., Tsiroulnikova O.M., Miloserdov I.A., Latypov R.A., Egorova E.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/950

HCV-инфекция – одна из наиболее частых причин, приводящих к развитию терминальных заболеваний печени – цирроза и гепатоцеллюлярной карциномы, основным методом лечения которых является ортотопическая трансплантация печени. Однако при сохраняющейся репликации вируса происходит 100% реинфицирование, что приводит к быстрому прогрессированию цирроза трансплантата и потери его функции. Стандартная интерферон-содержащая терапия малоэффективна при HCV-инфекции, особенно 1-го генотипа, как до трансплантации, так и после нее, а также имеет широкий спектр нежелательных явлений. В статье представлен успешный опыт лечения рецидива HCV-инфекции 1-го генотипа у пациента, перенесшего ретрансплантацию печени и прошедшего несколько курсов неэффективной противовирусной терапии.

HCV infection is one of the most common causes leading to the development of terminal liver diseases – cirrhosis and hepatocellular carcinoma, the main treatment for which is orthotopic liver transplantation. However, with continued virus replication, 100% reinfection occurs, which leads to the rapid progression of cirrhosis of the graft and the loss of its function. Standard interferon-containing therapy is ineffective for HCV infection, especially genotype 1, both before and after transplantation, and also has a wide range of adverse events. The article presents the successful experience of treating the recurrence of HCV infection 1 genotype in a patient who underwent liver transplantation and several courses of ineffective antiviral therapy.

хронический гепатит Срецидивтрансплантация печенипрепараты прямого противовирусного действияустойчивый вирусологический ответchronic hepatitis Crelapseliver transplantationdirect antiviral actionresistant virologic responseReferencesKlempnauer J, Castaing D, Neuhaus P et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012; 57: 675–688.Klempnauer J, Castaing D, Neuhaus P et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012; 57: 675–688.Thuluvath PJ, Guidinger MK, Fung JJ et al. Liver transplantation in the United States, 1999–2008. Am J Transplant. 2010; 10: 1003–1019.Thuluvath PJ, Guidinger MK, Fung JJ et al. Liver transplantation in the United States, 1999–2008. Am J Transplant. 2010; 10: 1003–1019.Roche B, Sebagh M, Canfora ML, Antonini T, Roque­Afonso A, Delvart V et al. Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008; 14: 1766–1777. doi: 10.1002/lt.21635.Roche B, Sebagh M, Canfora ML, Antonini T, Roque­Afonso A, Delvart V et al. Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008; 14: 1766–1777. doi: 10.1002/lt.21635.Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol Int. 2016 Sep; 10 (5): 749–761.Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol Int. 2016 Sep; 10 (5): 749–761.Picciotto FP, Tritto G, Lanza AG et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007; 46: 459–465.Picciotto FP, Tritto G, Lanza AG et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007; 46: 459–465.Watt K. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009; 9: 1707–1713.Watt K. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009; 9: 1707–1713.Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32: 673– 684.Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32: 673– 684.Firpi RJ, Clark V, Soldevila­Pico C et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transplantation. 2009; 15: 1063–1071.Firpi RJ, Clark V, Soldevila­Pico C et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transplantation. 2009; 15: 1063–1071.European Liver Transplant Registry [Internet]. http://www.eltr.org/ Patient Survival vs Primary Indication. Available from: http://www.eltr.org/Overall-indication-and-results.html.European Liver Transplant Registry [Internet]. http://www.eltr.org/ Patient Survival vs Primary Indication. Available from: http://www.eltr.org/Overall-indication-and-results.html.Zimmermann T, Bocher WO, Biesterfeld S et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007; 20: 583–590.Zimmermann T, Bocher WO, Biesterfeld S et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007; 20: 583–590.Jain A, Sharma R, Ryan C et al. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clin Transpl. 2010; 24: 104–111.Jain A, Sharma R, Ryan C et al. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clin Transpl. 2010; 24: 104–111.Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142: 1373–1383.Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142: 1373–1383.Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006; 6 (7): 1586–1599.Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006; 6 (7): 1586–1599.Raedler LA. Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. American Health & Drug Benefits. 2015; 8: 142–147.Raedler LA. Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. American Health & Drug Benefits. 2015; 8: 142–147.Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), copackaged [prescribing information]. North Chicago, IL: AbbVie Inc; February 2015.Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), copackaged [prescribing information]. North Chicago, IL: AbbVie Inc; February 2015.Kwo PY, Mantry PS, Coakley E et al. An interferonfree antiviral regimen for HCV after liver transplantation. The New England Journal of Medicine. 2014; 371: 2375–2382.Kwo PY, Mantry PS, Coakley E et al. An interferonfree antiviral regimen for HCV after liver transplantation. The New England Journal of Medicine. 2014; 371: 2375–2382.Yu ML, Chen YL, Huang CF et al. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. Journal of the Formosan Medical Association. 2018; 117: 518–526.Yu ML, Chen YL, Huang CF et al. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. Journal of the Formosan Medical Association. 2018; 117: 518–526.Tronina O, Durlik M, Wawrzynowicz­-Syczewska M et al. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/ PTV/r/+DSV±RBV). Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. Annals of Transplantation. 2017; 22: 199–207.Tronina O, Durlik M, Wawrzynowicz­-Syczewska M et al. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/ PTV/r/+DSV±RBV). Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. Annals of Transplantation. 2017; 22: 199–207.

The authors declare that there are no conflicts of interest present.